How Can We Help You?

Quick Info:

Find a Doctor Specialties (800) 213-3284

Go To Home PageBack

Multiple Myeloma Trials

Select Clinical Trial

Protocol Number: DRAMMATIC Study (SWOG 1803)

Protocol Title: PHASE III STUDY OF DARATUMUMAB/rHuPH20 (NSC- 810307) + LENALIDOMIDE OR LENALIDOMIDE AS POST-AUTOLOGOUS STEM CELL TRANSPLANT MAINTENANCE THERAPY IN PATIENTS WITH MULTIPLE MYELOMA (MM) USING MINIMAL RESIDUAL DISEASE TO DIRECT THERAPY DURATION

Eligibility: Men or women, ages 18 and older with Multiple Myeloma, after an autologous stem cell transplant

Contact Information: (910) 715-2200

Specialties
Clara McLean House
Make a Donation
News & Events